Stifel analyst Rick Wise lowered the firm’s price target on Silk Road Medical to $9 from $12 and keeps a Hold rating on the shares. The company’s Q3 results were in-line and its FY23 guidance was cut, the analyst tells investors. Outlook is currently uncertain due to the continued salesforce disruptions the company has faced, the firm adds. Until the firm hears about the new CEO’s initial perspectives and key initiatives and the company reports its FY24 outlook, the firm will remain on the sidelines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical backs FY23 revenue view $170M-$174M, consensus $171.55M
- Silk Road Medical reports Q3 EPS (33c), consensus (35c)
- Silk Road Medical Reports Third Quarter 2023 Financial Results
- Silk Road Medical names McKhann as CEO
- Silk Road Medical to Report Third Quarter 2023 Financial Results on November 8, 2023
